LifeCycle Pharma Announces Positive Phase III Results: LCP-Tacro™ Trial In Stable Kidney Transplant Patients
Links shared publicly online about this topic.
- 201total visits
LifeCycle Pharma Announces Positive Phase III Results: LCP-Tacro™ Trial In Stable Kidney Transplant Patients
LifeCycle Pharma A/S (OMX:LCP) reported that the company's lead product candidate, LCP-Tacro™, successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma
View full resource at medicalnewstoday.com
Tags: Kidney Health, Urinary System, Organ Transplantation, Organ Transplant Rejection Medication, Kidney Transplant, Pharma, Prograf, Transplantation
Most Recently Shared on June 22, 2011 at 7:05 am By:
LifeCycle Pharma Announces Positive Phase III Results: LCP-Tacro™ Trial In Stable Kidney Transplant Patients http://mnt.to/3Xv2
Also Shared By:
LifeCycle Pharma Announces Positive Results Of Phase 2 Clinical Trial For LCP-Tacro™ In De Novo Liver Transplant Patients
medicalnewstoday.com — “LifeCycle Pharma A/S (OMX: LCP) has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro™ tablets administered once-daily versus Progra” View full resource at medicalnewstoday.com
Most Recently Shared on January 7, 2011 at 2:05 pm By:
LifeCycle Pharma Announces Positive Results Of Phase 2 Clinical Trial For LCP-Tacro™ In De Novo Liver Transplant... http://mnt.to/3PJT
Advertisement
MNT Pharma News
@mnt_pharma
LifeCycle Pharma Announces Positive Results Of Phase 2 Clinical Trial For LCP-Tacro™ In De Novo Liver Transplant... http://mnt.to/3PJT
1 year ago...